Pritzker School of Molecular Engineering and.
Biological Sciences Division, University of Chicago, Chicago, Illinois, USA.
J Clin Invest. 2022 Jan 18;132(2). doi: 10.1172/JCI155255.
Peanut oral immunotherapy (OIT) was recently approved by the US FDA. However, not all patients respond to OIT, and there is a high likelihood of regaining sensitization to peanuts after cessation of treatment. It is important, therefore, to identify biomarkers that impact and predict OIT outcomes. In this issue of the JCI, Monian, Tu, and colleagues describe distinct subsets of peanut-reactive CD4+ Th cell phenotypes and gene signatures with relevance to OIT outcomes using single-cell RNA-Seq and paired T cell receptor (TCR) α/β sequencing. The insights obtained will inform the development of therapeutics that target these Th cell phenotypes or deplete peanut-specific Th2 cells to achieve sustained nonresponsiveness in food allergy.
花生口服免疫疗法（OIT）最近获得了美国 FDA 的批准。然而，并非所有患者对 OIT 都有反应，并且在治疗停止后重新致敏花生的可能性很高。因此，确定影响和预测 OIT 结果的生物标志物非常重要。在本期 JCI 中，Monian、Tu 和同事使用单细胞 RNA-Seq 和配对的 T 细胞受体（TCR）α/β测序，描述了与 OIT 结果相关的花生反应性 CD4+ Th 细胞表型和基因特征的不同亚群。获得的这些见解将为开发针对这些 Th 细胞表型的治疗方法或耗尽花生特异性 Th2 细胞以实现食物过敏的持续无反应性提供信息。
